RET Tyrosine Kinase and Medullary Thyroid Cells are Unaffected by Clinical Doses of STI571

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 3601-3606

  Skinner, Michael A ^a   Safford, Shawn D ^a   Freemerman, Alex J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gleevec; RET; STI571; TT cells

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN RET; PROTEIN TYROSINE KINASE;

ARTICLE; ASSAY; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; THYROID CELL; THYROID MEDULLARY CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; CELL DEATH; CELL DIVISION; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 0344442314     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Golden JP, DeMaro JA, Osborne PA, Milbrandt J and Johnson EM Jr: Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. Exp Neurol 158: 504-528, 1999.
2. Golden JP, Baloh RH, Kotzbauer PT, Lampe PA, Osborne PA, Milbrandt J and Johnson EM Jr: Expression of neurturin, GDNF, and their receptors in the adult mouse CNS. J Comp Neurol 398: 139-150, 1998.
3. Komminoth P: The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Virchows Arch 431: 1-9, 1997.
4. Le HN and Norton JA: Perspective on RET proto-oncogene and thyroid cancer. Cancer J 6: 50-57, 2000.
5. Manie S, Santoro M, Fusco A and Billaud M: The RET receptor: function in development and dysfunction in congenital malformation. Trends in Genetics 17: 580-589, 2001.
6. De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa A, Billaud M, Fusco A, Tsichlis PN and Santoro M: Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res 60: 3727-3731, 2000.
7. Murakami H, Iwashita T, Asai N, Shimono Y, Iwata Y, Kawai K and Takahashi M: Enhanced phosphatidylinositol 3-kinase and high phosphorylation state of its downstream signalling molecules mediated by RET with the MEN 2B mutation. Biochem Biophys Res Comm 262: 68-75, 1999.
8. Evans DB, Fleming JB, Lee JE, Cot G and Gagel RF: The surgical treatment of medullary thyroid carcinoma. Seminars Surg Oncol 16: 50-63, 1999.
9. Chen H, Roberts JR, Ball DW, Eisele DW, Baylin SB, Udelsman R and Bulkley GB: Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 227: 887-895, 1998.
10. Giuffrida D and Gharib H: Current diagnosis and management of medullary thyroid carcinoma. Annals Oncol 9: 695-701, 1998.
11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 2: 561-566, 1996.
12. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ and Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104, 1996.
13. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG and Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947-4952, 1997.
14. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Hematopoiesis 96: 925-932, 2000.
15. Savage GG and Antman KH: Drug therapy: Imatinib Mesylate - a new oral targeted therapy. N Engl J Med 346: 683-693, 2002.
16. Shtivelman E, Lifshitz B, Gale RP and Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315: 550-554, 1985.
17. DeMatteo RP: The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 9: 831-839, 2002.
18. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054-8, 2001.
19. Greco A, Roccato E, Miranda C, Cleris L, Formelli F and Pierotti MA: Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 92: 354-360, 2001.
20. George D: Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Seminars in Oncol 28: 27-33, 2001.
21. Cohen MS, Hussain HB and Moley JF: Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132: 960-967, 2002.
22. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Ple PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J and Curwen JO: Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Medic Chem 45: 1300-1312, 2002.
23. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
24. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001.
25. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R and Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042, 2001.
26. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A and Santoro M: The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 62: 1077-1082, 2002.
27. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A and Santoro M: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62: 7284-7290, 2002.
28. Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S: The protein kinase complement of the human genome. Science 298: 1912-1934, 2002.
29. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL and Hennequin LF: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-55, 2002.